The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)

Greg Durm, Nasser Hanna


There will be an estimated 228,150 new cases of lung cancer in the U.S. and approximately 2.1 million cases worldwide in 2019. In 2018, it is estimated that 1.76 million people worldwide died from lung cancer (1,2). Most people with lung cancer have locally advanced or metastatic disease at the time of diagnosis, and thus, the improvement of systemic therapies for this population is of critical importance (3).